A Double Blind Study for the Treatment of Acute Ulcerative Colitis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Warner Chilcott
ClinicalTrials.gov Identifier:
NCT00350415
First received: July 6, 2006
Last updated: April 15, 2013
Last verified: April 2013
  Purpose

A Double-blind, Randomized, 6-week, Parallel-group Design Clinical trial to assess the Safety and Efficacy of Asacol 4.8 g/day (800 mg mesalamine tablet) versus Asacol 2.4 g/day (400 mg mesalamine tablet) for the Treatment of Moderately Active Ulcerative Colitis (ASCEND III).


Condition Intervention Phase
Ulcerative Colitis
Drug: Mesalamine
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Double-blind, Randomized, 6-week, Parallel-group Design Clinical Trial to Assess the Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day for the Treatment of Moderately Active Ulcerative Colitis.

Resource links provided by NLM:


Further study details as provided by Warner Chilcott:

Primary Outcome Measures:
  • Proportion of patients (ITT) in each treatment group who achieve treatment success, defined as symptomatic and endoscopic improvement from baseline at Week 6. [ Time Frame: Week 6 ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Proportion of patients (ITT) in pre-defined subgroups in each treatment group who achieve treatment success, defined as symptomatic and endoscopic improvement from baseline at Week 6 and Week 3. [ Time Frame: week 3 and 6 ] [ Designated as safety issue: No ]

Enrollment: 772
Study Start Date: June 2006
Study Completion Date: May 2007
Primary Completion Date: May 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Asacol 2.4 g/day (400 mg tablet)
Drug: Mesalamine

Asacol 400g/day (400 mg tablet), oral, for 6 weeks

OR

Asacol 4,8 g/day (800 mg table), oral, for 6 weeks

Active Comparator: 2
Asacol 4,8 g/day (800 mg tablet), oral, for 6 weeks
Drug: Mesalamine

Asacol 400g/day (400 mg tablet), oral, for 6 weeks

OR

Asacol 4,8 g/day (800 mg table), oral, for 6 weeks


Detailed Description:

This is a double-blind, randomized, multi-center, multi-national, active-control study in patients who are experiencing a moderately active flare of UC. Patients will be randomly assigned to receive either Asacol 2.4 g/day (400 mg tablet) or Asacol 4.8 g/day (800 mg tablet) for 6 weeks. Patients will be randomized to one of the 2 treatment groups in a 1:1 ratio. The objective of the study is to evaluate the safety and efficacy of Asacol 4.8 g/day (800 mg tablet) compared to Asacol 2.4 g/day (400 mg tablet) in this patient population. Following successful screening, patients will be randomized to one of the two treatment arms. Patients will be evaluated after 6 weeks of treatment with an interim visit after 3 weeks.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients 18-75 years with a confirmed diagnosis of moderately active flare of ulcerative colitis.
  • Female patients need to be postmenopausal or using adequate contraception.

Exclusion Criteria:

  • Patients with isolated proctitis
  • Patients with comorbidities or an investigative or commercialized treatments confounding interpretation of study results or compromising patients' safety in the trial.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00350415

  Hide Study Locations
Locations
United States, Alabama
Research Facility
Alabaster, Alabama, United States, 35007
Research Facility
Birmingham, Alabama, United States, 35209
United States, Arizona
Research Facility
Tucson, Arizona, United States, 85712
United States, Arkansas
Research Facility
Fayetteville, Arkansas, United States, 72703
Research Facility
Little Rock, Arkansas, United States, 72205
United States, California
Research Facility
Anaheim, California, United States, 92801
Research Facility
Burbank, California, United States, 91505
Research Facility
Encinitas, California, United States, 93024
Research Facility
Los Angeles, California, United States, 90274
Research Facility
Los Angeles, California, United States, 90067
Research Facility
Mission Hills, California, United States, 91345
Research Facility
Orange, California, United States, 92868
Research Facility
Pasadena, California, United States, 91105
Research Facility
Roseville, California, United States, 95661
Research Facility
Sacramento, California, United States, 95825
Research Facility
San Carlos, California, United States, 94070
Research Facility
San Francisco, California, United States, 94115
United States, Colorado
Research Facility
Lakewood, Colorado, United States, 80215
Research Facility
Littleton, Colorado, United States, 80120
United States, Connecticut
Research Facility
Hamden, Connecticut, United States, 06518-3691
United States, Florida
Research Facility
Deland, Florida, United States, 32720
Research Facility
Harbor, Florida, United States, 34684
Research Facility
Hollywood, Florida, United States, 33021
Research Facility
Jacksonville, Florida, United States, 32256
Research Facility
Panama City, Florida, United States, 33405
Research Facility
Zephyrhills, Florida, United States, 33542
United States, Georgia
Research Facility
Atlanta, Georgia, United States, 30033
Research Facility
Savannah, Georgia, United States, 31405
United States, Illinois
Research Facility
Arlington Heights, Illinois, United States, 60005
Research Facility
Chicago, Illinois, United States, 60637
United States, Kansas
Research Facility
Topeka, Kansas, United States, 60606
United States, Kentucky
Research Facility
Louisville, Kentucky, United States, 40292
United States, Louisiana
Research Facility
Baton Rouge, Louisiana, United States, 70809
Research Facility
Shreveport, Louisiana, United States, 71103
United States, Maryland
Research Facility
Baltimore, Maryland, United States, 21215
Research Facility
Chevy Chase, Maryland, United States, 20815
Research Facility
Reisterstown, Maryland, United States, 21136
United States, Massachusetts
Research Facility
Boston, Massachusetts, United States, 02115
United States, Michigan
Research Facility
Columbia, Michigan, United States, 65212
United States, Minnesota
Research Facility
Minneapolis, Minnesota, United States, 55455
Research Facility
Rochester, Minnesota, United States, 55905
United States, Mississippi
Research Facility
Tupelo, Mississippi, United States, 38801
United States, Missouri
Research Facility
Kansas City, Missouri, United States, 64131
Research Facility
St. Louis, Missouri, United States, 63128
United States, Nebraska
Research Facility
Omaha, Nebraska, United States, 68131
Research Facility
Scottsbluff, Nebraska, United States, 69361
United States, New Jersey
Research Facility
Egg Harbor Township, New Jersey, United States, 08234
United States, New York
Research Facility
Binghamton, New York, United States, 13903
Research Facility
Garden City, New York, United States, 11530
Research Facility
Great Neck, New York, United States, 11021
Research Facility
Huntington, New York, United States, 11743
Research Facility
New York, New York, United States, 10021
Research Facility
Rochester, New York, United States, 14642
Research Facility
Troy, New York, United States, 12180
United States, North Carolina
Research Facility
Charlotte, North Carolina, United States, 28262
Research Facility
Wilmington, North Carolina, United States, 28401
United States, North Dakota
Research Facility
Bismarck, North Dakota, United States, 58501-1640
Research Facility
Fargo, North Dakota, United States, 58104
United States, Ohio
Research Facility
Akron, Ohio, United States, 44302
Research Facility
Cincinnati, Ohio, United States, 45242
Research Facility
Dayton, Ohio, United States, 45440
Research Facility
Warren, Ohio, United States, 44484
United States, Oregon
Research Facility
Portland, Oregon, United States, 97220
United States, Pennsylvania
Research Facility
Beaver Falls, Pennsylvania, United States, 15010
Research Facility
Philadelphia, Pennsylvania, United States, 19107
Research Facility
York, Pennsylvania, United States, 17403
United States, South Carolina
Research Facility
Columbia, South Carolina, United States, 29203
United States, Tennessee
Research Facility
Kingsport, Tennessee, United States, 37660
Research Facility
Memphis, Tennessee, United States, 38120
Research Facility
Nashville, Tennessee, United States, 37232
United States, Texas
Research Facility
Austin, Texas, United States, 78743
Research Facility
San Antonio, Texas, United States, 78205
United States, Utah
Research Facility
Murray, Utah, United States, 84107
Research Facility
Ogden, Utah, United States, 84405
United States, Vermont
Research Facility
Burlington, Vermont, United States, 05401
United States, Virginia
Research Facility
Chesapeake, Virginia, United States, 23320
United States, Washington
Research Facility
Redmond, Washington, United States, 98052
United States, Wisconsin
Research Facility
Milwaukee, Wisconsin, United States, 53215
Belarus
Research Facility
Gornel, Gormel, Belarus
Research Facility
Grodno, Belarus, 230017
Research Facility
Minsk, Belarus, 220013
Research Facility
Vitebsk, Belarus, 210037
Canada, Alberta
Research Facility
Edmonton, Alberta, Canada, T6G 2X8
Canada, British Columbia
Research Facility
Abbotsford, British Columbia, Canada, V2S 3N5
Research Facility
Vancouver, British Columbia, Canada, V5Z 112
Canada, Ontario
Research Facility
Guelph, Ontario, Canada, N1H 3R3
Research Facility
Hamilton, Ontario, Canada, L8N 3Z5
Research Facility
London, Ontario, Canada, N6A 5K8
Research Facility
Ottawa, Ontario, Canada, K1H 8L6
Research Facility
Toronto, Ontario, Canada, M3N 2V7
Canada, Quebec
Research Facility
Levis, Quebec, Canada, G6V 3Z1
Research Facility
Longheuil, Quebec, Canada, J4N 1E1
Research Facility
Montreal, Quebec, Canada, H31 1E2
Research Facility
Quebec City, Quebec, Canada, G1R 2J6
Research Facility
Rimouski, Quebec, Canada, G5L 5T1
Canada, Saskatchewan
Research Facility
Saskatoon, Saskatchewan, Canada, S7K 1N4
Canada
Research Facility
Quebec, Canada, G1L 3L5
Croatia
Research Facility
Rijeka, Croatia, 51000
Research Facility
Zagreb, Croatia, 10000
Czech Republic
Research Facility
Kralove, Czech Republic, 500 12
Research Facility
Pavlov, Czech Republic
Research Facility
Praha 2, Czech Republic, 120 00
Research Facility
Strakonice, Czech Republic, 3886 29
Research Facility
Usti nad Labem, Czech Republic, 401 13
Estonia
Research Facility
Tallinn, Estonia, 10138
Research Facility
Tartu, Estonia, 51014
Hungary
Research Facility
Argenti Dome ter, Hungary, 1-3
Research Facility
Budapest, Hungary
Research Facility
Nagyerdei krt, Hungary, 98
Latvia
Research Facility
Riga, Latvia, LV-1002
Lithuania
Research Facility
Santariskiu, Vilnius, Lithuania, LT-08661
Research Facility
Kaunas, Lithuania, LT-50009
Research FacilityPanevezys
Panevezys, Lithuania, LT-35144
Poland
Research Facility
Bydgoszcz, Poland, 85-681
Research Facility
Czestochowa, Poland, 42-200
Research Facility
Krakow, Poland, 31-501
Research Facility
Lodz, Poland, 90-153
Research Facility
Pruszkow, Poland, 05-800
Research Facility
Sopot, Poland, 81-756
Research Facility
Warszawa, Poland, 02-57
Research Facility
Wtoctawek, Poland, 87-800
Puerto Rico
Research Facility
San Juan, Puerto Rico, 5067
Romania
Research Facility
Bucuresti 1, Bucuresti, Romania, 010825
Research Facility
Cluj-napoca, Romania, 400162
Research Facility
Iasi, Romania, 700111
Russian Federation
Research Facility
Moscow, Mowcow, Russian Federation, 129110
Research Facility
Nizhny Novgorod, Russian Federation, 603126
Research Facility
St. Petersburg, Russian Federation, 196247
Serbia
Research Facility
Beograd, Serbia, 11080
Research Facility
Novi Sad, Serbia, 21000
Ukraine
Research Facility
Zabolotnogo, Odesa, Ukraine, 65025
Research Facility
Kharkiv, Ukraine, 61037
Research Facility
Kyiv, Ukraine, 04053
Research Facility
Simpheropol, Ukraine, 95000
Research Facility
Zaporizhzhya, Ukraine, 69050
Sponsors and Collaborators
Warner Chilcott
Investigators
Study Director: Piotr Krzeski, MD Procter and Gamble
  More Information

Additional Information:
No publications provided

Responsible Party: Warner Chilcott
ClinicalTrials.gov Identifier: NCT00350415     History of Changes
Obsolete Identifiers: NCT00336440
Other Study ID Numbers: 2006444
Study First Received: July 6, 2006
Last Updated: April 15, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Warner Chilcott:
ulcerative colitis, inflammatory bowel disease

Additional relevant MeSH terms:
Colitis
Colitis, Ulcerative
Ulcer
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Intestinal Diseases
Inflammatory Bowel Diseases
Pathologic Processes
Mesalamine
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Anti-Inflammatory Agents
Therapeutic Uses
Antirheumatic Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on July 31, 2014